Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Completed · Phase 1
Conditions studied: Kidney Cancer, Melanoma (Skin)
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.
Key facts
- Study ID
- NCT00006022
- Run by
- Virginia Commonwealth University
- People needed
- 17
- Starts
- 2000-09-01
- Expected to finish
- 2004-01-01
- Last updated by the study team
- 2015-12-14
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
- Massey Cancer Center — Richmond, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.